Literature DB >> 11925917

[A case of rebamipide-induced pneumonitis].

Hirofumi Mochizuki1, Katsuya Fujimori, Eiichi Suzuki, Masaaki Arakawa, Fumitake Gejyo.   

Abstract

A 75-year-old man who complained of progressive dyspnea was admitted to our hospital. He had been treated with rebamipide at an outpatient clinic for the preceding seven months. Atrial blood gas values obtained on admission indicated hypoxemia. Chest radiographs and CT films revealed diffuse interstitial infiltration and minimal pleural effusion. Bronchoalveolar lavage fluid showed an increase in the total cell number, the percentages of eosinophils and lymphocytes, and a decrease in the CD4/CD8 ratio. Transbronchial lung biopsy specimens had thickened alveolar septa with lymphocyte infiltration within the air spaces. After the discontinuation of rebamipide, oral prednisolone was administered, and the patient's symptoms and pulmonary shadows quickly improved. A lymphocyte stimulating test for rebamipide was positive. A challenge test for rebamipide was not performed because informed consent could not be obtained. On the basis of these findings, our diagnosis was rebamipide-induced pneumonitis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11925917

Source DB:  PubMed          Journal:  Nihon Kokyuki Gakkai Zasshi        ISSN: 1343-3490


  2 in total

1.  A case of imatinib-related obstructive bronchiolitis followed long term.

Authors:  Chika Yajima; Nariaki Kokuho; Kazutoshi Toriyama; Junichiro Kawagoe; Yuki Togashi; Jun Matsubayashi; Hideaki Nakayama; Yasuhiro Setoguchi; Shinji Abe
Journal:  Respir Med Case Rep       Date:  2020-04-04

2.  The risk of pulmonary adverse drug reactions of rebamipide and other drugs for acid-related diseases: An analysis of the national pharmacovigilance database in South Korea.

Authors:  Bo Ram Yang; Jae-Young Lee; Myeong Gyu Kim
Journal:  J Dig Dis       Date:  2022-02-09       Impact factor: 3.366

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.